https://www.scmp.com/rss/522250/feed The latest news and top stories on National Medical Products Administration. A prominent Beijing, China-based governmental regulatory agency, the National Medical Products Administration (NMPA) is dedicated to safeguarding public health by regulating drugs, medical devices, and cosmetics. Its primary mission involves ensuring the safety and efficacy of these products through comprehensive approval, registration, and post-market supervision. The NMPA’s main areas of activity include setting... en https://assets.i-scmp.com/static/img/icons/scmp-meta-1200x630.png https://www.scmp.com Julie Zhang Julie Zhang At least 10 weight-loss injections and oral pills are lining up for regulatory approval in China, in a market projected to reach about US$14 billion by 2030. Novo Nordisk’s blockbuster semaglutide, which generated about US$35 billion in global revenue last year, lost patent protection in China on March 20, clearing the way for rivals. The rush comes as China’s drug regulator accelerates approvals of innovative therapies, helped by a surge in out-licensing deals with global pharmaceutical... https://www.scmp.com/business/china-business/article/3347869/chinas-weight-loss-drug-makers-take-global-giants-novo-nordisk-patent-expires?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3347869/chinas-weight-loss-drug-makers-take-global-giants-novo-nordisk-patent-expires?utm_source=rss_feed Thu, 26 Mar 2026 03:00:08 +0000 Julie Zhang Julie Zhang Chinese drug makers’ licensing deals more than doubled in 2025 from a year earlier to a record high, propelled by dozens of multibillion-dollar agreements between Hong Kong and mainland China-listed firms and global pharmaceutical giants. Last year, 157 out-licensing deals worth US$135.7 billion were signed, compared with 94 transactions worth US$51.9 billion in 2024, state media reported, citing data released by the National Medical Products Administration (NMPA), China’s drugs regulator, last... https://www.scmp.com/business/china-business/article/3339011/chinese-drug-makers-strike-record-us136-billion-out-licensing-deals-2025?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3339011/chinese-drug-makers-strike-record-us136-billion-out-licensing-deals-2025?utm_source=rss_feed Thu, 08 Jan 2026 00:30:09 +0000 Phoebe Zhang Phoebe Zhang Bi Jingquan, China’s former top food and drug regulator who received an international accolade for promoting innovation, has been expelled from the Communist Party and removed from public office on corruption charges. An investigation found that Bi had accepted gifts, money, trips and banquets and borrowed vehicles from private business owners, a statement from the Central Commission for Discipline Inspection (CCDI) said on Monday. The statement also said Bi had “allowed others to pay for him,... https://www.scmp.com/news/china/politics/article/3335712/former-chief-chinas-food-and-drug-watchdog-ousted-communist-party?utm_source=rss_feed https://www.scmp.com/news/china/politics/article/3335712/former-chief-chinas-food-and-drug-watchdog-ousted-communist-party?utm_source=rss_feed Tue, 09 Dec 2025 08:00:15 +0000 Eric Ng Eric Ng Shares in Jiangsu Hengrui Pharmaceuticals, China’s largest drug maker by market value, got a boost on Thursday after it announced its fifth licensing deal of the year, widening its access to the key emerging market of India. The Shanghai-listed company, which went public in Hong Kong in May and raised HK$9.9 billion (US$1.26 billion), struck a deal with Glenmark Specialty of Mumbai-based Glenmark Pharmaceuticals, it said in a stock exchange filing late on Wednesday. The agreement was part of an... https://www.scmp.com/business/article/3326777/chinas-hengrui-gets-boost-fifth-drug-licensing-deal-year-adds-india-partner?utm_source=rss_feed https://www.scmp.com/business/article/3326777/chinas-hengrui-gets-boost-fifth-drug-licensing-deal-year-adds-india-partner?utm_source=rss_feed Thu, 25 Sep 2025 04:48:31 +0000 Alice Li Alice Li In the summer of 2015, a time when China’s pharmaceutical market was in a phase of rapid expansion, a sudden regulatory change sent tremors through the industry: drug companies would need to audit the clinical trial data for all pending applications. If withdrawn within a month of the announcement, firms could avoid penalties for submitting flawed applications, but hiding or falsifying data would court severe punishments, including multi-year filing bans. The response from the industry indicated... https://www.scmp.com/economy/china-economy/article/3324487/chinas-biotech-industry-gaining-us-can-tariffs-hold-them-back?utm_source=rss_feed https://www.scmp.com/economy/china-economy/article/3324487/chinas-biotech-industry-gaining-us-can-tariffs-hold-them-back?utm_source=rss_feed Fri, 05 Sep 2025 22:00:13 +0000 Holly Chik Holly Chik With a growing number of Chinese affected by hearing loss, an Australian implant maker is leveraging the special medical tourism zone in Hainan to provide faster access to its latest device. Cochlear introduced its new smart system in China in June, making the country one of the first global markets to launch the technology – through Hainan, the southern island province, and Hong Kong. Introducing it via the Boao Lecheng international medical tourism pilot zone has meant patients can receive... https://www.scmp.com/news/china/science/article/3316832/cochlear-takes-fast-lane-it-brings-new-hearing-device-chinese-market?utm_source=rss_feed https://www.scmp.com/news/china/science/article/3316832/cochlear-takes-fast-lane-it-brings-new-hearing-device-chinese-market?utm_source=rss_feed Fri, 04 Jul 2025 04:00:16 +0000